Crystallization equipment for pharmaceutical APIs

01Overview and value chain#

Markers EC: ICH Q8/Q9/Q10 & ICH Q13 continuous manufacturing | OECD: Bio-pharmaceuticals | Regulator: FDA (USA), EMA (EU), NMPA (China)

Crystallization equipment for pharmaceutical APIs is the set of vessels, coolers and continuous contactors that drive a purified active pharmaceutical ingredient out of solution into a solid crystal of defined polymorph, particle-size distribution and purity. It is the unit operation on which bioavailability, filterability and downstream drying all depend, and it is where the molecule becomes a processable solid. Three geometries dominate the field: batch draft-tube-baffled (DTB) and Oslo crystallizers for mid-volume APIs, plug-flow and MSMPR continuous crystallizers for high-volume steady-state production, and fractional-melt crystallizers for ultra-high-purity (electronic- or pharma-grade) isolation without solvent handling. The platform is mid-transformation along four axes: inline FBRM and PVM probes that close the loop on chord-length and crystal-shape in real time under ICH Q8 Quality-by-Design; the shift from batch to ICH Q13 continuous crystallization for high-volume APIs; automated parallel screening (Crystal16, Crystalline) that maps polymorph/solvent space in a single overnight run; and fractional-melt crystallization as a green, low-solvent purification route for high-value intermediates.

The key directions of pharmaceutical crystallization equipment are:

1. Automated parallel crystallization screening (Crystal16, Crystalline): Technobis platforms that run 16 or 96 parallel small-volume crystallizations under software control, sweeping solvent, cooling rate and anti-solvent composition to map the polymorph/solvent landscape before scale-up.
2. Industrial forced-circulation and draft-tube-baffled crystallizers (GEA Messo): the mid-volume workhorse geometry — forced-circulation (FC), draft-tube-baffled (DTB) and Oslo growth-type crystallizers for steroid, vitamin and antibiotic APIs.
3. Continuous and melt crystallization (Sulzer Chemtech): plug-flow and MSMPR continuous crystallizers for steady-state ICH Q13 production, and fractional-melt crystallizers that exploit small impurity partition coefficients for electronic- and pharma-grade purity without solvent handling.
4. Inline PAT and closed-loop control (Mettler-Toledo FBRM/PVM, ReactIR): inline laser and video probes that track crystal chord-length, shape and supersaturation in real time, enabling Quality-by-Design closed-loop cooling under ICH Q8/Q9/Q10.

Sectoral value chain#

[API solution preparation] ──> [crystallizer (DTB / continuous / melt)] ──> [crystal suspension]
                                                │
                                  (inline FBRM/PVM + supersaturation control)
                                                │
                                                ▼
[dried API] <─── [drying] <─── [solid-liquid separation] <─────┘

Value chain levels#

Cross-cutting technologies of the sector:

• Inline FBRM/PVM PAT (FBRM/PVM PAT): focused-beam reflectance and particle-video microscopy probes for real-time chord-length and crystal-shape tracking.
• Continuous crystallization (Continuous Crystallization): plug-flow and MSMPR geometries running at steady state under ICH Q13.
• Melt crystallization (Melt Crystallization): fractional freezing for ultra-high-purity isolation without solvent handling.

02US#

The United States is the largest demand market for pharmaceutical crystallization equipment — most of the world’s top-20 API manufacturers run US-based process-development and validation groups — and FDA’s ICH Q8 Quality-by-Design and ICH Q13 continuous-manufacturing guidances are the regulatory drivers behind real-time FBRM/PVM closed-loop cooling and the batch-to-continuous transition. The crystallizer OEM base is European, so the US regional block describes the demand-and-adoption side rather than an indigenous OEM.

ICH Q8 QbD adoption, continuous-manufacturing validation, process-development demand#

• FDA ICH Q8/Q9/Q10 Quality-by-Design: the framework that requires a defined polymorph control strategy and real-time release, pulling FBRM/PVM PAT into every new API filing.
• ICH Q13 continuous-manufacturing adoption: US filers lead on continuous crystallization submissions for high-volume APIs, validating plug-flow and MSMPR geometries.
• US process-development demand: the top-20 API manufacturers’ US process-development groups are the primary buyers of Technobis parallel-screening and Mettler-Toledo automated-lab-reactor platforms.

03CN#

China is the fastest-growing production geography for pharmaceutical crystallization equipment: domestic API manufacturers supplying steroids, vitamins (ascorbic acid, B-group, D3) and antibiotics are scaling mid-volume DTB and Oslo crystallizer capacity, and NMPA’s adoption of ICH Q8/Q9/Q10/Q13 harmonises the Quality-by-Design and continuous- manufacturing framework with FDA and EMA. The crystallizer OEM base remains predominantly imported (European), so the CN regional block is held qualitative.

API scale-out, NMPA ICH Q8/Q13 alignment, imported OEM base#

• Domestic API production scale-out: steroid, vitamin and antibiotic manufacturers run mid-volume DTB and Oslo crystallizer trains built around European (GEA, Sulzer) and PAT (Mettler-Toledo) hardware.
• NMPA ICH Q8/Q9/Q10/Q13 alignment: harmonised Quality-by-Design and continuous-manufacturing guidance, framing the regulatory route for FBRM/PVM closed-loop and continuous crystallization.
• Imported OEM base: the crystallizer and PAT OEM layer is predominantly European; domestic firms localise media, solvent recovery and downstream drying rather than the crystallizer itself.

04EU#

Europe is the centre of pharmaceutical crystallization equipment manufacturing — all four crystallizer OEM classes and the dominant PAT platform are European. Technobis (Alkmaar, NL) builds the automated parallel-screening platforms; Sulzer Chemtech (Winterthur, CH) builds continuous and fractional-melt crystallizers; GEA Messo builds the industrial DTB, Oslo and forced-circulation workhorses; Syrris (Royston, UK, an Agilent company) supplies flow-chemistry and continuous-crystallization platforms; and Mettler-Toledo supplies the FBRM/PVM/ReactIR PAT suite. EMA’s ICH Q8/Q13 implementation completes the framework.

crystallizer OEMs, PAT platforms, EMA ICH Q8/Q13#

• Technobis — Crystal16 & Crystalline: automated parallel crystallization screening platforms mapping polymorph and solvent space across 16–96 small-volume vessels.
• Sulzer Chemtech — SuPro & melt crystallizers: plug-flow continuous crystallizers and fractional-melt units for electronic- and pharma-grade purification.
• GEA Messo — DTB, Oslo, FC crystallizers: the industrial forced-circulation, draft-tube-baffled and Oslo growth-type workhorses for steroid, vitamin and antibiotic APIs.
• Syrris — Asia flow-chemistry/crystallization (Agilent): continuous-flow and batch-crystallization platforms for hazardous-reaction scale-up.
• Mettler-Toledo — FBRM, PVM, ReactIR: the inline PAT suite (focused-beam reflectance, particle video microscopy, mid-IR) that closes the crystallization control loop under ICH Q8.

05Leading companies and research institutes#

06Tech stack and innovations#

The stack combines the crystallizer vessel, the inline PAT probes and the Quality-by-Design control strategy into one closed, validated process.

1. Crystallizer geometries (Crystallizer Geometries):
   • batch draft-tube-baffled (DTB) and Oslo growth-type crystallizers (GEA Messo) for mid-volume APIs;
   • plug-flow and MSMPR continuous crystallizers (Sulzer SuPro) for steady-state ICH Q13 production;
   • fractional-melt crystallizers for ultra-high-purity, low-solvent isolation.
2. Inline PAT probes (Inline PAT Probes):
   • FBRM (focused-beam reflectance) tracking crystal chord-length distribution in real time;
   • PVM (particle video microscopy) imaging crystal shape and habit;
   • ReactIR mid-IR tracking solution concentration and supersaturation for feedback cooling.
3. Parallel screening & QbD control (Parallel Screening & QbD Control):
   • Technobis Crystal16 / Crystalline parallel platforms sweeping solvent and cooling-rate space overnight;
   • Quality-by-Design cooling profiles under ICH Q8 that hold the process inside the design space for polymorph control.

07Value chains and production pipelines#

Industrial pipeline of a pharma-API crystallization train (ICH Q8/Q13)#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. API solution prep      │ ───> │ 2. Crystallization        │
└───────────────────────────┘      └───────────────────────────┘
                                                  │
                                                  ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Solid-liquid separation│ <─── │ 3. PAT closed-loop control│
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Drying                 │ ───> │ 6. Polymorph & release QC │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: API solution preparation

The purified API is dissolved in solvent or anti-solvent at a set concentration and temperature to give a clear, undersaturated starting solution.

Stage 2: Crystallization

Supersaturation is generated — by cooling, anti-solvent addition, evaporation or melt — in the crystallizer (DTB, Oslo, FC, plug-flow or melt), nucleating and growing crystals to a target polymorph and size.

Stage 3: PAT closed-loop control

Inline FBRM tracks crystal chord-length, PVM images crystal habit and ReactIR tracks supersaturation, feeding a Quality-by-Design cooling profile under ICH Q8 that holds the process inside the design space.

Stage 4: Solid-liquid separation

The crystal slurry is filtered or decanted from the mother liquor on a filter dryer or pusher centrifuge, yielding a wet crystal cake.

Stage 5: Drying

The wet cake is dried under vacuum or in a conical dryer to the target residual-solvent specification set by ICH Q3D.

Stage 6: Polymorph and release QC

X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC) and laser particle-size analysis confirm the polymorph, habit and size distribution before batch release against the regulatory specification.